These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1167 related articles for article (PubMed ID: 20498393)

  • 1. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
    Sargent DJ; Marsoni S; Monges G; Thibodeau SN; Labianca R; Hamilton SR; French AJ; Kabat B; Foster NR; Torri V; Ribic C; Grothey A; Moore M; Zaniboni A; Seitz JF; Sinicrope F; Gallinger S
    J Clin Oncol; 2010 Jul; 28(20):3219-26. PubMed ID: 20498393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
    J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Taieb J; Shi Q; Pederson L; Alberts S; Wolmark N; Van Cutsem E; de Gramont A; Kerr R; Grothey A; Lonardi S; Yoshino T; Yothers G; Sinicrope FA; Zaanan A; André T
    Ann Oncol; 2019 Sep; 30(9):1466-1471. PubMed ID: 31268130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy.
    Zhao F; Li E; Shen G; Dong Q; Ren D; Wang M; Zhao Y; Liu Z; Ma J; Xie Q; Liu Z; Li Z; Gao L; Zhao J
    J Gastroenterol; 2023 Jul; 58(7):622-632. PubMed ID: 37036516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
    Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
    J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
    Bertagnolli MM; Niedzwiecki D; Compton CC; Hahn HP; Hall M; Damas B; Jewell SD; Mayer RJ; Goldberg RM; Saltz LB; Warren RS; Redston M
    J Clin Oncol; 2009 Apr; 27(11):1814-21. PubMed ID: 19273709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
    Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
    Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):844-8. PubMed ID: 25620482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
    JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    Sinicrope FA; Mahoney MR; Smyrk TC; Thibodeau SN; Warren RS; Bertagnolli MM; Nelson GD; Goldberg RM; Sargent DJ; Alberts SR
    J Clin Oncol; 2013 Oct; 31(29):3664-72. PubMed ID: 24019539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
    Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
    Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
    Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
    Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
    Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.
    Donada M; Bonin S; Barbazza R; Pettirosso D; Stanta G
    BMC Gastroenterol; 2013 Feb; 13():36. PubMed ID: 23446022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
    Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS
    Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.
    Ma J; Zhang Y; Shen H; Kapesa L; Liu W; Zeng M; Zeng S
    Tumour Biol; 2015 Dec; 36(12):9599-609. PubMed ID: 26142736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microsatellite instability testing and its role in the management of colorectal cancer.
    Kawakami H; Zaanan A; Sinicrope FA
    Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
    Niedzwiecki D; Hasson RM; Lenz HJ; Ye C; Redston M; Ogino S; Fuchs CS; Compton CC; Mayer RJ; Goldberg RM; Colacchio TA; Saltz LB; Warren RS; Bertagnolli MM
    Oncologist; 2017 Jan; 22(1):107-114. PubMed ID: 27821793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.